# NAD+: Research Overview — AgeDefy Peptide > A literature summary of NAD+ (nicotinamide adenine dinucleotide) and its precursors NMN and NR: redox biology, sirtuin and PARP signaling, human clinical trial evidence, and the open questions in longevity research. Nicotinamide adenine dinucleotide — the coenzyme at the center of energy metabolism and DNA repair — whose age-related decline has made it the most-trialed molecule in human longevity research. ## The short version **NAD+** stands for nicotinamide adenine dinucleotide. It is not a peptide — it is a small coenzyme built from two nucleotides joined by a phosphate bridge — but it belongs on a longevity research desk because it is arguably the most-studied molecule in the cellular aging field. Every living cell uses NAD+ constantly: it carries electrons through energy metabolism to make ATP, and it is consumed by signaling enzymes — sirtuins and PARPs — that govern DNA repair and gene regulation [4]. Here is the central tension the research has identified. NAD+ tissue levels fall measurably with age, in part because a NAD-consuming enzyme called CD38 rises as we grow older [6]. That decline is linked to metabolic dysfunction. Oral precursors — NMN and NR — reliably raise blood NAD+ in human trials [2][5]. What those elevated levels actually do in the body is where the evidence becomes genuinely uncertain: a 2025 review in *Nature Metabolism* concluded that human trials have shown limited clinical efficacy and that tissue-specific NAD+ data remain sparse [1]. This page summarizes what was studied; it is not advice and lists no human dose. ## What it is NAD+ is a dinucleotide — a molecule made of nicotinamide mononucleotide (NMN) and adenosine monophosphate (AMP) joined by two bridging phosphate groups. Its molecular formula is C21H27N7O14P2. The oxidized form is written NAD+; the reduced form, which carries two extra hydrogen atoms, is NADH. Both forms are constantly interconverted in cellular metabolism. When people talk about "boosting NAD+" they mean raising the available pool of the oxidized form, which is the form consumed by sirtuin and PARP signaling enzymes. Two main precursors are used in research and supplement contexts: nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). Both enter the NAD+ biosynthesis salvage pathway in cells and raise blood NAD+ in human studies. The regulatory and marketplace status of these precursors differs from NAD+ itself — the FDA has contested whether NMN qualifies as a dietary supplement, having been investigated as a drug. IV NAD+ therapy is compounded, not FDA-approved, and one compounded formulation was subject to a Class I recall for endotoxin contamination. ## How it works NAD+ plays two distinct roles in the cell. As a *redox carrier* it shuttles electrons — picking them up as NADH in glycolysis and the TCA cycle, dropping them at the mitochondrial electron transport chain to drive ATP synthesis. This is the metabolic backbone of energy production in every cell. As a *signaling substrate* it is consumed rather than recycled. Three enzyme families compete for the NAD+ pool: **sirtuins** (SIRT1-7, which use NAD+ to remove acetyl groups from proteins and regulate gene expression, metabolism, and stress responses), **PARPs** (particularly PARP1, which uses NAD+ to repair DNA breaks), and **CD38/CD157** (ectoenzymes whose activity rises with age and inflammation) [4]. The competition among these consumers is part of the reason age-related NAD+ decline matters: CD38 has been identified as the dominant driver of that decline in mouse tissue, and CD38 knockout mice are protected against age-related NAD+ loss and mitochondrial dysfunction [6]. NAMPT — nicotinamide phosphoribosyltransferase — is the rate-limiting enzyme in the salvage pathway that recycles nicotinamide back into NAD+ and is the main throughput control for intracellular NAD+ levels. ## What the research shows *Oral NMN in human adults.* A multicenter double-blind RCT across middle-aged adults found that oral NMN at 300, 600, or 900 mg/day for 60 days dose-dependently raised blood NAD+ at days 30 and 60 versus placebo (p≤0.001); the 600 mg/day group also showed improved walking distance and quality-of-life scores, with no safety concerns at any dose [2]. This multicenter design, across several sites, strengthens generalizability relative to single-site pilot work. *Muscle insulin sensitivity in prediabetic women.* Ten weeks of oral NMN at 250 mg/day significantly improved muscle insulin sensitivity as measured by hyperinsulinemic-euglycemic clamp in prediabetic, postmenopausal women; body composition and HbA1c did not change [3]. This was the first controlled human evidence that NMN supplementation improves a specific metabolic outcome in a defined population. *Nicotinamide riboside dose-response.* NR at 100, 300, or 1000 mg/day for 8 weeks dose-dependently raised whole-blood NAD+ by 22%, 51%, and 142% respectively in healthy overweight adults; there was no flushing and no significant adverse-event differences from placebo at any dose, and NR did not elevate LDL cholesterol or disrupt one-carbon metabolism [5]. *CD38 as the mechanistic driver of decline.* In mice, CD38 deletion preserves NAD+ levels and SIRT3 activity, improves mitochondrial function, and protects metabolic health with age, identifying CD38 as the primary enzyme responsible for age-related NAD+ depletion [6]. *Cardiac NAD+ and heart failure.* Using human myocardium tissue and a murine model of heart failure with preserved ejection fraction (HFpEF), NAD+ repletion restored the activity of the ketogenic enzyme HMGCS2, increased fatty acid oxidation, and rescued cardiac function — an effect that required HMGCS2 and was abolished when HMGCS2 was knocked out in cardiomyocytes [7]. *The 2025 evidence synthesis.* A comprehensive 2025 review in *Nature Metabolism* surveying the human clinical trial record concluded that consistent blood NAD+ elevation is well documented with oral precursors, but that age-related NAD+ decline has been confirmed in only a limited number of human tissue studies, translation to hard clinical endpoints is inconsistent across trials, and more human studies of systemic and tissue-specific NAD+ metabolism are needed — the current body of evidence rests heavily on rodent models [1]. ## Reported effects, cautions & safety Several cautions are well documented in the peer-reviewed literature and controversies are worth naming plainly: - *Oral NAD+ itself is poorly absorbed.* Most experts consider NMN and NR the rational oral approaches; plain oral "NAD+" capsules may be largely ineffective because the intact molecule does not readily cross the gut wall into cells [1]. - *IV NAD+ wellness therapy.* Infusions are marketed aggressively but rest on minimal controlled evidence. Infused NAD+ is rapidly cleared from plasma, and infusions can cause chest or abdominal discomfort, flushing, and nausea if administered too quickly. One compounded injectable formulation was recalled by the FDA at the Class I level for elevated bacterial endotoxin [1]. - *Theoretical cancer concern.* A theoretical concern exists that boosting NAD+ could fuel the metabolism of existing cancers: NAD+ supports rapidly proliferating cells, and its role in oncology is context-dependent. The research community has noted this as an open question warranting caution in cancer populations [4]. - *Translation to hard endpoints.* Raising blood NAD+ is well demonstrated; translation to longevity, disease prevention, or meaningful clinical outcomes in humans remains unproven as of the 2025 review [1]. - *Rodent extrapolation.* Much of the strongest anti-aging data comes from mouse and rat models and may not extrapolate directly to human biology [1]. - *Product quality.* Supplement-grade NAD+ precursors vary in purity and actual content; third-party testing is not guaranteed. ![NAD+ energy metabolism and mitochondrial redox illustration in cold steel blue](/images/nad.webp) ## Where it fits in longevity research Among the two molecules on this desk, NAD+ has the deeper and broader human evidence base — human clinical trials with oral precursors are in the dozens, and blood NAD+ elevation is one of the best-documented pharmacodynamic effects in the entire longevity-supplement field [2][5]. What remains genuinely unsettled is whether that pharmacodynamic effect translates to clinical benefit: the most authoritative 2025 synthesis of the human trial record calls the efficacy evidence limited [1]. MOTS-c, by contrast, is still mostly an animal story with early human observational data [10][11]. Read alongside [MOTS-c](/mots-c), NAD+ illustrates the field's central challenge: measurable biology, real preclinical signals, and a human evidence base that is real but still catching up to the preclinical enthusiasm. See the [comparison page](/compare) for how the two line up. --- A calm literature desk for cellular aging research — citations and context, not prescriptions and not products.